OC 10426
Latest Information Update: 14 Dec 2001
At a glance
- Originator Ontogen
- Class
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 21 Sep 1998 Profile reviewed
- 21 Nov 1996 Preclinical development for Cancer in USA (Unknown route)